Equities research analysts predict that Unum Therapeutics Inc (NASDAQ:UMRX) will report earnings of ($0.36) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Unum Therapeutics’ earnings. Unum Therapeutics posted earnings per share of ($0.34) during the same quarter last year, which suggests a negative year-over-year growth rate of 5.9%. The company is scheduled to announce its next quarterly earnings results on Monday, August 10th.

According to Zacks, analysts expect that Unum Therapeutics will report full year earnings of ($0.53) per share for the current year. For the next financial year, analysts anticipate that the business will post earnings of ($0.59) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.10. Unum Therapeutics had a negative net margin of 99.09% and a negative return on equity of 83.39%. The firm had revenue of $7.03 million for the quarter, compared to analysts’ expectations of $3.00 million.

A number of equities research analysts have issued reports on the stock. Wedbush reissued a “hold” rating and set a $1.00 target price on shares of Unum Therapeutics in a research note on Sunday, March 29th. HC Wainwright decreased their target price on shares of Unum Therapeutics from $18.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, March 27th. Zacks Investment Research raised shares of Unum Therapeutics from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research note on Saturday, May 30th. Finally, Morgan Stanley lowered shares of Unum Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, March 3rd. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $2.90.

A hedge fund recently raised its stake in Unum Therapeutics stock. Renaissance Technologies LLC lifted its holdings in Unum Therapeutics Inc (NASDAQ:UMRX) by 2,626.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 354,458 shares of the company’s stock after purchasing an additional 341,458 shares during the period. Renaissance Technologies LLC owned 1.16% of Unum Therapeutics worth $255,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 29.19% of the company’s stock.

NASDAQ UMRX traded up $0.01 on Tuesday, hitting $0.46. 253,238 shares of the stock were exchanged, compared to its average volume of 434,832. Unum Therapeutics has a 52-week low of $0.30 and a 52-week high of $2.84. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.37 and a quick ratio of 3.37. The company has a market capitalization of $13.55 million, a price-to-earnings ratio of -0.53 and a beta of 1.32. The company’s 50-day moving average price is $0.52 and its two-hundred day moving average price is $0.59.

About Unum Therapeutics

Unum Therapeutics Inc, a biopharmaceutical company, develops and commercializes immunotherapy products for cancer. The company is developing ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL).

Further Reading: The Role of a Fiduciary and Individual Investors

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.